CINECA IRIS Institutional Research Information System

BRINGHEN, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.134
EU - Europa 3.818
AS - Asia 2.642
SA - Sud America 234
OC - Oceania 121
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.014
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.883
IT - Italia 1.262
CN - Cina 996
JP - Giappone 612
SE - Svezia 372
FR - Francia 343
GB - Regno Unito 298
SG - Singapore 287
IE - Irlanda 267
DE - Germania 262
IN - India 226
CA - Canada 193
ES - Italia 192
NL - Olanda 119
AU - Australia 110
BR - Brasile 100
FI - Finlandia 100
AT - Austria 97
VN - Vietnam 95
UA - Ucraina 88
KR - Corea 87
CH - Svizzera 70
PL - Polonia 64
HK - Hong Kong 56
ID - Indonesia 55
TR - Turchia 54
BE - Belgio 44
IL - Israele 44
MX - Messico 43
GR - Grecia 41
PT - Portogallo 39
CO - Colombia 36
HU - Ungheria 28
TW - Taiwan 27
RU - Federazione Russa 26
AR - Argentina 23
PE - Perù 23
CL - Cile 22
DK - Danimarca 20
NO - Norvegia 20
PK - Pakistan 17
TH - Thailandia 16
SN - Senegal 15
TN - Tunisia 15
UY - Uruguay 15
RO - Romania 12
MY - Malesia 11
CZ - Repubblica Ceca 10
HR - Croazia 10
MA - Marocco 10
NZ - Nuova Zelanda 10
SA - Arabia Saudita 10
KW - Kuwait 9
MK - Macedonia 9
NG - Nigeria 8
QA - Qatar 8
AE - Emirati Arabi Uniti 7
TT - Trinidad e Tobago 6
BO - Bolivia 5
AM - Armenia 4
EC - Ecuador 4
EG - Egitto 4
IR - Iran 4
MT - Malta 4
PH - Filippine 4
UZ - Uzbekistan 4
AD - Andorra 3
BG - Bulgaria 3
CU - Cuba 3
DZ - Algeria 3
EE - Estonia 3
GF - Guiana Francese 3
JO - Giordania 3
KE - Kenya 3
SI - Slovenia 3
BD - Bangladesh 2
IQ - Iraq 2
KY - Cayman, isole 2
LU - Lussemburgo 2
MD - Moldavia 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
ZA - Sudafrica 2
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
GL - Groenlandia 1
IS - Islanda 1
JM - Giamaica 1
NP - Nepal 1
PA - Panama 1
PF - Polinesia Francese 1
PY - Paraguay 1
TG - Togo 1
TJ - Tagikistan 1
Totale 13.014
Salva come PNG Salva come JPEG
Città #
Fairfield 384
Chandler 330
Beijing 264
Redwood City 263
Dublin 254
Torino 236
Ashburn 234
Florence 220
Singapore 212
Cambridge 186
Houston 175
Tokyo 173
Woodbridge 154
Wilmington 137
Turin 133
Ann Arbor 127
Nyköping 127
Seattle 125
Santa Clara 118
Vienna 85
Dearborn 84
Medford 77
Ottawa 77
Shanghai 73
Princeton 72
Columbus 71
New York 71
Los Angeles 63
Duncan 60
Guangzhou 60
Pisa 60
London 59
Villeurbanne 59
Jakarta 53
Nanjing 52
Hangzhou 51
Portland 51
Chicago 47
Dong Ket 47
Madrid 44
Paris 44
Minneapolis 42
Boston 41
Milan 41
Indianapolis 40
Rochester 40
Jacksonville 38
San Diego 37
Toronto 37
Raritan 35
Warsaw 34
Seoul 30
Hyderabad 29
Norwalk 29
Rome 29
Baltimore 28
Helsinki 28
Philadelphia 28
Perth 27
Providence 27
Sydney 27
Newbury Park 26
São Paulo 24
Boardman 23
Brussels 23
Amsterdam 22
Chengdu 22
Barcelona 21
Osaka 21
Saint Paul 21
San Mateo 21
Athens 20
Charlotte 20
Breda 19
Hebei 19
Hong Kong 19
Lima 19
St Louis 19
Brzeg 18
Fukuoka 18
Pittsburgh 18
Santiago 18
Atlanta 17
Budapest 17
Flushing 17
San Francisco 17
Tel Aviv 17
Wuhan 17
Bengaluru 16
Durham 16
Xian 16
Changchun 15
Montevideo 15
Mumbai 15
Munich 15
Phoenix 15
Salt Lake City 15
Toledo 15
Campi Bisenzio 14
Zurich 14
Totale 6.593
Salva come PNG Salva come JPEG
Nome #
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 2.828
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 1.162
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 798
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 588
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group 417
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 388
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 332
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 304
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 299
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials 295
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 289
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 260
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 252
Determining treatment intensity in elderly patients with multiple myeloma 230
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 216
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 197
How is patient care for multiple myeloma advancing? 192
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 191
Treatment of newly diagnosed elderly multiple myeloma 171
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report 149
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis 148
Emerging drugs and combinations to treat multiple myeloma 146
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups 145
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 144
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 142
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 142
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 126
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) 122
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 120
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. 116
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 109
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma 109
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 107
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 101
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials 99
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 95
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score 92
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network 90
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 89
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients 89
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. 84
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis 83
Treatment of newly diagnosed elderly multiple myeloma 81
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 80
Monoclonal antibodies to treat multiple myeloma: A dream come true 79
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center 75
Multiple myeloma patients undergoing carfilzomib: Development and validation of a risk score for cardiovascular adverse events prediction 66
Systemic virotherapy for multiple myeloma 63
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 63
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma 62
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 61
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 61
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 59
Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy 58
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. 57
Melphalan and its role in the management of patients with multiple myeloma 54
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. 54
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant 54
The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma 52
Approach to the Older Adult With Multiple Myeloma 49
New treatment strategies for elderly myeloma patients 49
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study 46
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma 39
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians 22
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience 17
Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study 17
Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment 16
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review 6
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor 5
M‐protein‐related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone 1
Totale 13.402
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.006
article - articoli 0
book - libri 0
conference - conferenze 626
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020909 0 0 0 0 89 124 116 100 205 100 97 78
2020/20212.283 74 134 164 147 206 221 195 202 232 198 202 308
2021/20222.442 174 173 149 240 176 139 269 141 127 201 300 353
2022/20232.550 151 208 184 207 178 337 183 232 256 172 246 196
2023/20242.245 176 240 161 240 191 213 169 214 60 185 200 196
2024/20251.332 198 212 282 287 353 0 0 0 0 0 0 0
Totale 13.402